Vericel (VCEL) Gains from Investment Securities (2012 - 2018)
Vericel (VCEL) reported Gains from Investment Securities of -$420000.0 for Q3 2018, down 139.62% on a YoY basis from $1.1 million in Q3 2017, and down 1235.14% sequentially from $37000.0 in Q2 2018.
Vericel (VCEL) Gains from Investment Securities (2012 - 2018) Analysis & Trends
Vericel (VCEL) has 7 years of Gains from Investment Securities data on file, last reported at -$420000.0 in Q3 2018.
- For the quarter ending Q3 2018, Gains from Investment Securities fell 139.62% year-over-year to -$420000.0; the trailing twelve-month figure through Jun 2019 stood at -$420000.0 (down 111.2% YoY), and the FY2018 full-year result was $2.5 million, up 882.1% from the prior year.
- Gains from Investment Securities eased to -$420000.0 in Q3 2018, from $37000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.9 million in Q1 2018 to a low of -$1.9 million in Q2 2016.
- A 5-year average of $130736.8 and a median of -$107000.0 in 2017 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities slumped 1633.93% in 2016 and soared 2816.82% in 2018, its largest moves.
- Tracing VCEL's Gains from Investment Securities over 5 years: stood at -$128000.0 in 2014, then surged by 46.88% to -$68000.0 in 2015, then soared by 245.59% to $99000.0 in 2016, then tumbled by 357.58% to -$255000.0 in 2017, then sank by 64.71% to -$420000.0 in 2018.
- Business Quant data shows VCEL's Gains from Investment Securities at -$420000.0 in Q3 2018, $37000.0 in Q2 2018, and $2.9 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Vericel | 2.32 Bn | 2.17 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -420,000.00 |
| Sep 30, 2018 | -420,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Mar 31, 2018 | 2.91 Mn |
| Mar 31, 2018 | 2.91 Mn |
| Dec 31, 2017 | -255,000.00 |
| Dec 31, 2017 | -255,000.00 |
| Sep 30, 2017 | 1.06 Mn |
| Sep 30, 2017 | 1.06 Mn |
| Jun 30, 2017 | -441,000.00 |
| Jun 30, 2017 | -441,000.00 |
| Mar 31, 2017 | -107,000.00 |
| Mar 31, 2017 | -107,000.00 |
| Dec 31, 2016 | 99,000.00 |
| Dec 31, 2016 | 99,000.00 |
| Sep 30, 2016 | 203,000.00 |
| Sep 30, 2016 | 203,000.00 |
| Jun 30, 2016 | -1.94 Mn |
| Jun 30, 2016 | -1.94 Mn |